Purpose: Hepatic arterioportal fistula (HAPF) is an uncommon complication of hepatic trauma, which can manifest with abdominal pain and the sequelae of portal hypertension months to years after injury. The purpose of this study is to present cases of HAPF from our busy urban trauma center and make recommendations for management.
Methods: One hundred and twenty-seven patients with high-grade penetrating liver injuries (American Association for the Surgery of Trauma [AAST] - Grades IV-V) between January 2019 and October 2022 were retrospectively reviewed. Five patients were identified with an acute hepatic arterioportal fistula following abdominal trauma from our ACS-verified adult Level 1 trauma center. Institutional experience with overall surgical management is described and reviewed with the current literature.
Results: Four of our patients presented in hemorrhagic shock requiring emergent operative intervention. The first patient had postoperative angiography and coil embolization of the HAPF. Patients 2 through 4 underwent damage control laparotomy with temporary abdominal closure followed by postoperative transarterial embolization with gelatin sponge particles (Gelfoam) or combined Gelfoam/n-butyl cyanoacrylate. The final patient went directly for angiography and Gelfoam embolization after identification of the HAPF. All 5 patients had resolution of HAPF on follow-up imaging with continued post management for traumatic injuries.
Conclusion: Hepatic arterioportal fistula can present as a complication of hepatic injury and manifest with significant hemodynamic aberrations. Although surgical intervention was required to achieve hemorrhage control in almost all cases, management of HAPF in the setting of high-grade liver injuries was achieved successfully with modern endovascular techniques. A multidisciplinary approach to such injuries is necessary to optimize care in the acute setting following traumatic injury.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724846 | PMC |
http://dx.doi.org/10.1177/15385744231165155 | DOI Listing |
Am J Case Rep
December 2024
I Department of Radiology and Diagnostic Imaging, Norbert Barlicki Memorial Teaching Hospital No. 1, Medical University of Łódź, Łódź, Poland.
BACKGROUND Arterioportal fistulas (APFs) are abnormal connections between the arterial and portal venous systems, leading to portal hypertension (PH) and symptoms such as gastrointestinal bleeding, splenomegaly, and hepatic pain. Symptoms typically appear by the age of 2 years in about 75% of cases. CASE REPORT A 7-year-old boy with an asymptomatic APF developed life-threatening complications following a Clostridium difficile infection.
View Article and Find Full Text PDFQuant Imaging Med Surg
December 2024
Department of Ultrasonography, Hangzhou Red Cross Hospital, Hangzhou, China.
Ann Surg Oncol
January 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
J Hepatocell Carcinoma
September 2024
Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China.
Background And Objectives: Transarterial chemoembolization (TACE) and I seed implantation are methods used to treat hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), PVTT often associated with arterioportal shunts(APS), there are few reports on the combined use of TACE and I seed implantation for such patients. This study aimed to evaluate the efficacy and safety of TACE combined with PVTT I seed implantation in the treatment of HCC patients with APS.
Methods: Forty-two patients diagnosed with HCC combined with PVTT and APS between January 2020 and December 2021 were included.
Br J Radiol
December 2024
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Objective: To evaluate the efficacy and safety of drug eluting bead transarterial chemoembolization (D-TACE) combined with apatinib/camrelizumab in patients with advanced hepatocellular carcinoma (HCC) and hepatic arterioportal shunts (APSs).
Methods: From January 2021 to December 2022, the consecutive medical records of patients with advanced HCC and APS receiving D-TACE combined with apatinib/camrelizumab were reviewed for eligibility. Overall survival (OS), progression-free survival (PFS), tumour response, and adverse events (AEs) were assessed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!